Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00389740 | A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189) | PHASE3 | COMPLETED | 400 | — | — | Apr 2, 2001 | Jan 16, 2003 | Aug 14, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0217, /Duration of Treatment : 12 Months | DRUG | - |
| Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months | DRUG | - |
Inclusion Criteria: * Patient is postmenopausal (or surgically menopausal) for at least 6 months * Patient must be diagnosed with osteoporosis * Patient has spinal anatomy suitable for DEXA of the lumbar spine Exclusion Criteria: * Patient is receiving or has received treatment prior to randomiza...